MwanzoRGEN • NASDAQ
add
Repligen Corp
$ 162.33
Baada ya Saa za Kazi:(0.00%)0.00
$ 162.33
Imefungwa: 23 Jan, 17:35:58 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 167.93
Bei za siku
$ 160.22 - $ 169.78
Bei za mwaka
$ 102.97 - $ 182.06
Thamani ya kampuni katika soko
9.14B USD
Wastani wa hisa zilizouzwa
elfu 607.65
Uwiano wa bei na mapato
6,304.08
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 188.80M | 21.91% |
Matumizi ya uendeshaji wa biashara | 87.84M | 5.00% |
Mapato halisi | 14.91M | 2,379.97% |
Kiwango cha faida halisi | 7.90 | 1,980.95% |
Mapato kwa kila hisa | 0.46 | 6.98% |
EBITDA | 32.69M | 156.90% |
Asilimia ya kodi ya mapato | 12.86% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 748.75M | -4.49% |
Jumla ya mali | 2.92B | 3.29% |
Jumla ya dhima | 840.62M | 3.28% |
Jumla ya hisa | 2.08B | — |
hisa zilizosalia | 56.29M | — |
Uwiano wa bei na thamani | 4.54 | — |
Faida inayotokana na mali | 1.09% | — |
Faida inayotokana mtaji | 1.15% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 14.91M | 2,379.97% |
Pesa kutokana na shughuli | 48.10M | -2.48% |
Pesa kutokana na uwekezaji | -7.78M | -32.84% |
Pesa kutokana na ufadhili | elfu -239.00 | 99.66% |
Mabadiliko halisi ya pesa taslimu | 39.89M | 258.41% |
Mtiririko huru wa pesa | 41.60M | 9.85% |
Kuhusu
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1981
Makao Makuu
Tovuti
Wafanyakazi
1,778
